265:
190:
579:
22:
79:
447:
Yang, Yili; Kitagaki, Jirouta; Dai, Ren-Ming; Tsai, Yien Che; Lorick, Kevin L.; Ludwig, Robert L.; Pierre, Shervon A.; Jensen, Jane P.; Davydov, Ilia V.; Oberoi, Pankaj; Li, Chou-Chi H.; Kenten, John H.; Beutler, John A.; Vousden, Karen H.; Weissman, Allan M. (1 October 2007).
147:
489:
Kapuria V, Peterson LF, Showalter HD, et al. (Aug 15, 2011). "Protein cross-linking as a novel mechanism of action of a ubiquitin-activating enzyme inhibitor with anti-tumor activity".
656:
40:
627:
526:"Ubiquitin-activating enzyme E1 inhibitor PYR-41 attenuates angiotensin II-induced activation of dendritic cells via the IκBa/NF-κB and MKP1/ERK/STAT1 pathways"
304:
419:
and ubiquitination-dependent protein degradation or other ubiquitination-mediated cellular activities. In addition, PYR-41 inhibits degradation of
620:
613:
288:
InChI=1S/C17H13N3O7/c1-2-26-17(23)10-3-5-11(6-4-10)19-16(22)13(15(21)18-19)9-12-7-8-14(27-12)20(24)25/h3-9H,2H2,1H3,(H,18,21)/b13-9-
279:
58:
646:
382:
222:
405:
243:
185:
401:
424:
91:
260:
593:
113:
555:
506:
471:
450:"Inhibitors of Ubiquitin-Activating Enzyme (E1), a New Class of Potential Cancer Therapeutics"
597:
167:
545:
537:
498:
461:
327:
123:
231:
651:
590:
264:
189:
586:
550:
525:
416:
376:
640:
398:
178:
211:
466:
449:
409:
578:
502:
354:
158:
559:
510:
475:
364:
198:
541:
375:
Except where otherwise noted, data are given for materials in their
146:
136:
78:
420:
15:
248:
312:
CCOC(=O)C1=CC=C(C=C1)N2C(=O)/C(=C\C3=CC=C(O3)(=O))/C(=O)N2
601:
36:
31:
may be too technical for most readers to understand
210:
122:
657:Antineoplastic and immunomodulating drug stubs
621:
8:
442:
440:
628:
614:
263:
188:
166:
70:
549:
465:
230:
59:Learn how and when to remove this message
43:, without removing the technical details.
436:
309:
284:
259:
100:)-4--3,5-dioxopyrazolidin-1-yl}benzoate
179:
291:Key: ARGIPZKQJGFSGQ-LCYFTJDESA-N
41:make it understandable to non-experts
7:
575:
573:
408:. It was also reported to increase
201:
600:. You can help Knowledge (XXG) by
415:PYR-41 also blocks the downstream
14:
577:
524:Chen C, et al. (Jun 2014).
77:
20:
379:(at 25 °C , 100 kPa).
406:ubiquitin-activating enzyme E1
1:
467:10.1158/0008-5472.CAN-07-0568
673:
572:
503:10.1016/j.bcp.2011.05.012
373:
359:371.3 g/mol
320:
300:
275:
106:
90:
85:
76:
647:4-Aminobenzoate esters
402:irreversible inhibitor
92:Preferred IUPAC name
73:
383:Infobox references
71:
609:
608:
542:10.1111/imm.12255
491:Biochem Pharmacol
460:(19): 9472–9481.
425:tumour suppressor
391:Chemical compound
389:
388:
244:CompTox Dashboard
148:Interactive image
69:
68:
61:
664:
630:
623:
616:
591:immunomodulatory
581:
574:
564:
563:
553:
521:
515:
514:
486:
480:
479:
469:
444:
328:Chemical formula
268:
267:
252:
250:
234:
214:
203:
192:
181:
170:
150:
126:
81:
74:
64:
57:
53:
50:
44:
24:
23:
16:
672:
671:
667:
666:
665:
663:
662:
661:
637:
636:
635:
634:
570:
568:
567:
523:
522:
518:
488:
487:
483:
454:Cancer Research
446:
445:
438:
433:
392:
385:
380:
348:
344:
340:
336:
330:
316:
313:
308:
307:
296:
293:
292:
289:
283:
282:
271:
253:
246:
237:
217:
204:
173:
153:
140:
129:
116:
102:
101:
65:
54:
48:
45:
37:help improve it
34:
25:
21:
12:
11:
5:
670:
668:
660:
659:
654:
649:
639:
638:
633:
632:
625:
618:
610:
607:
606:
587:antineoplastic
582:
566:
565:
536:(2): 307–319.
516:
497:(4): 341–349.
481:
435:
434:
432:
429:
417:ubiquitination
399:cell permeable
390:
387:
386:
381:
377:standard state
374:
371:
370:
369:1.5±0.1 g/cm3
367:
361:
360:
357:
351:
350:
346:
342:
338:
334:
331:
326:
323:
322:
318:
317:
315:
314:
311:
303:
302:
301:
298:
297:
295:
294:
290:
287:
286:
278:
277:
276:
273:
272:
270:
269:
261:DTXSID30416554
256:
254:
242:
239:
238:
236:
235:
227:
225:
219:
218:
216:
215:
207:
205:
197:
194:
193:
183:
175:
174:
172:
171:
163:
161:
155:
154:
152:
151:
143:
141:
134:
131:
130:
128:
127:
119:
117:
112:
109:
108:
104:
103:
95:
94:
88:
87:
83:
82:
67:
66:
49:September 2014
28:
26:
19:
13:
10:
9:
6:
4:
3:
2:
669:
658:
655:
653:
650:
648:
645:
644:
642:
631:
626:
624:
619:
617:
612:
611:
605:
603:
599:
596:article is a
595:
592:
588:
583:
580:
576:
571:
561:
557:
552:
547:
543:
539:
535:
531:
527:
520:
517:
512:
508:
504:
500:
496:
492:
485:
482:
477:
473:
468:
463:
459:
455:
451:
443:
441:
437:
430:
428:
426:
422:
418:
413:
411:
407:
403:
400:
396:
384:
378:
372:
368:
366:
363:
362:
358:
356:
353:
352:
332:
329:
325:
324:
319:
310:
306:
299:
285:
281:
274:
266:
262:
258:
257:
255:
245:
241:
240:
233:
229:
228:
226:
224:
221:
220:
213:
209:
208:
206:
200:
196:
195:
191:
187:
184:
182:
180:ECHA InfoCard
177:
176:
169:
165:
164:
162:
160:
157:
156:
149:
145:
144:
142:
138:
133:
132:
125:
121:
120:
118:
115:
111:
110:
105:
99:
93:
89:
84:
80:
75:
63:
60:
52:
42:
38:
32:
29:This article
27:
18:
17:
602:expanding it
584:
569:
533:
529:
519:
494:
490:
484:
457:
453:
414:
394:
393:
107:Identifiers
97:
55:
46:
30:
410:sumoylation
321:Properties
186:100.213.089
124:418805-02-4
96:Ethyl 4-{(4
641:Categories
530:Immunology
431:References
412:in cells.
355:Molar mass
232:HT54RAN9JZ
159:ChemSpider
135:3D model (
114:CAS Number
560:24456201
511:21621524
476:17909057
551:4008238
365:Density
349:
212:5335621
199:PubChem
168:4492747
72:PYR-41
35:Please
652:Furans
558:
548:
509:
474:
395:PYR-41
305:SMILES
86:Names
585:This
397:is a
280:InChI
137:JSmol
598:stub
594:drug
556:PMID
507:PMID
472:PMID
423:, a
223:UNII
589:or
546:PMC
538:doi
534:142
499:doi
462:doi
421:p53
404:of
249:EPA
202:CID
39:to
643::
554:.
544:.
532:.
528:.
505:.
495:82
493:.
470:.
458:67
456:.
452:.
439:^
427:.
339:13
335:17
629:e
622:t
615:v
604:.
562:.
540::
513:.
501::
478:.
464::
347:7
345:O
343:3
341:N
337:H
333:C
251:)
247:(
139:)
98:Z
62:)
56:(
51:)
47:(
33:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
